Clinical Trial Update: Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of L-FMAU in chronic Hepatitis B was terminated; the update specifically notes termination of the L-FMAU-201 placebo group.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• L-FMAU

Snippet

Sponsor: Bukwang Pharmaceutical | Conditions: Hepatitis B | Phase 2 | Status: TERMINATED